Publication:
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

Simple item page
dc.contributor.authorKahraman, Seda
dc.contributor.authorErul, Enes
dc.contributor.authorSeyyar, Mustafa
dc.contributor.authorGumusay, Ozge
dc.contributor.authorBayram, Ertugrul
dc.contributor.authorDemirel, Burcin Cakan
dc.contributor.authorAcar, Omer
dc.contributor.authorAksoy, Sercan
dc.contributor.authorBaytemur, Naziyet Kose
dc.contributor.authorSahin, Elif
dc.contributor.authorCabuk, Devrim
dc.contributor.authorBasaran, Gul
dc.contributor.authorPaydas, Semra
dc.contributor.authorYaren, Arzu
dc.contributor.authorGuven, Deniz Can
dc.contributor.authorErdogan, Atike Pinar
dc.contributor.authorDemirci, Umut
dc.contributor.authorYasar, Alper
dc.contributor.authorBayoglu, Ibrahim Vedat
dc.contributor.authorHizal, Mutlu
dc.contributor.authorGulbagci, Burcu
dc.contributor.authorPaksoy, Nail
dc.contributor.authorDavarci, Sena Ece
dc.contributor.authorYilmaz, Funda
dc.contributor.authorDogan, Ozlem
dc.contributor.authorOrhan, Sibel Oyucu
dc.contributor.authorKayikcioglu, Erkan
dc.contributor.authorAytac, Ali
dc.contributor.authorKeskinkilic, Merve
dc.contributor.authorMocan, Eda Eylemer
dc.contributor.authorUnal, Olcun Umit
dc.contributor.authorAydin, Esra
dc.contributor.authorYucel, Hakan
dc.contributor.authorIsik, Deniz
dc.contributor.authorEren, Onder
dc.contributor.authorUluc, Basak Oyan
dc.contributor.authorOzcelik, Melike
dc.contributor.authorHacibekiroglu, Ilhan
dc.contributor.authorAydiner, Adnan
dc.contributor.authorDemir, Hacer
dc.contributor.authorOksuzoglu, Berna
dc.contributor.authorCilbir, Ebru
dc.contributor.authorCubukcu, Erdem
dc.contributor.authorCetin, Bulent
dc.contributor.authorOktay, Esin
dc.contributor.authorErol, Cihan
dc.contributor.authorOkutur, Sadi Kerem
dc.contributor.authorYildirim, Nilgun
dc.contributor.authorAlkan, Ali
dc.contributor.authorSelcukbiricik, Fatih
dc.contributor.authorAksoy, Asude
dc.contributor.authorKarakas, Yusuf
dc.contributor.authorOzkanli, Gulhan
dc.contributor.authorDuman, Berna Bozkurt
dc.contributor.authorAydin, Dincer
dc.contributor.authorDulgar, Ozgecan
dc.contributor.authorEr, Muhammed Muhiddin
dc.contributor.authorTeker, Fatih
dc.contributor.authorYavuzsen, Tugba
dc.contributor.authorAykan, Musa Baris
dc.contributor.authorInal, Ali
dc.contributor.authorIriagac, Yakup
dc.contributor.authorKalkan, Nurhan Onal
dc.contributor.authorKeser, Murat
dc.contributor.authorSakalar, Teoman
dc.contributor.authorMenekse, Serkan
dc.contributor.authorKut, Engin
dc.contributor.authorBilgin, Burak
dc.contributor.authorKaraoglanoglu, Muge
dc.contributor.authorSunar, Veli
dc.contributor.authorOzdemir, Ozlem
dc.contributor.authorTurhal, Nazim Serdar
dc.contributor.authorKaradurmus, Nuri
dc.contributor.authorYalcin, Bulent
dc.contributor.authorSendur, Mehmet Ali Nahit
dc.contributor.buuauthorOYUCU ORHAN, SİBEL
dc.contributor.buuauthorÇUBUKÇU, ERDEM
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı.
dc.contributor.orcid0000-0001-8217-3471
dc.contributor.researcheridETP-1691-2022
dc.contributor.researcheridAAJ-8314-2021
dc.date.accessioned2024-10-07T08:37:15Z
dc.date.available2024-10-07T08:37:15Z
dc.date.issued2023-05-03
dc.description.abstractBackground: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference.
dc.identifier.doi10.2217/fon-2022-1287
dc.identifier.issn1479-6694
dc.identifier.urihttps://doi.org/10.2217/fon-2022-1287
dc.identifier.urihttps://www.tandfonline.com/doi/full/10.2217/fon-2022-1287
dc.identifier.urihttps://hdl.handle.net/11452/45952
dc.identifier.wos000991646700001
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherFuture Medicine Ltd
dc.relation.journalFuture Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectCdk 4
dc.subject6 inhibitors
dc.subjectHer2-negative metastatic breast cancer
dc.subjectHr-positive
dc.subjectLetrozole
dc.subjectOncology
dc.titleTreatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
dc.typeArticle
dc.typeEarly Access
dspace.entity.typePublication
relation.isAuthorOfPublication25a81c16-220e-4bd6-83fd-e2a28071f81f
relation.isAuthorOfPublicationf971677f-09c5-4463-bf01-3c6341fbe5f7
relation.isAuthorOfPublication.latestForDiscovery25a81c16-220e-4bd6-83fd-e2a28071f81f

Files

Collections

Yeni Yayınlar